The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Level Of Market Value Growth Is Predicted For The Neurotrophic Keratitis Treatment Market From 2026 To 2030?
The neurotrophic keratitis treatment market has experienced rapid expansion in its size over recent years. Projections indicate its value will increase from $1.47 billion in 2025 to $1.99 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 36.1%. This historical expansion is linked to factors such as the growing occurrence of corneal disorders associated with diabetes, a rise in herpes simplex eye infection cases, the proliferation of specialized ophthalmology clinics, enhanced clinician understanding of neurotrophic keratitis, and the broadened availability of hospital-based eye care provisions.
The neurotrophic keratitis treatment market size is projected to experience substantial expansion over the upcoming years, reaching $6.78 billion by 2030, with a remarkable compound annual growth rate (CAGR) of 35.8%. This anticipated growth during the forecast period is propelled by several factors, including developments in regenerative ophthalmic therapies, a rise in approvals for rhNGF-based medications, an expanding aging demographic susceptible to nerve degeneration, increased funding for rare eye disease research, and enhanced availability of sophisticated eye care in developing economies. Significant developments anticipated during this timeframe encompass the increasing integration of recombinant human nerve growth factor treatments, a growing inclination towards less invasive corneal repair methods, a heightened emphasis on early diagnosis and intervention, the wider availability of homecare-centric ophthalmic treatment options, and innovations in techniques for preserving amniotic membranes.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12968&type=smp
What Leading Drivers Are Supporting The Neurotrophic Keratitis Treatment Market Expansion?
An anticipated driver for the neurotrophic keratitis treatment market’s expansion is the increasing incidence of eye diseases. These conditions encompass various ailments impacting the eyes’ structure and operation, frequently resulting in compromised vision or complete blindness. Factors contributing to this surge in eye disease prevalence include an aging population, evolving lifestyle habits, and a higher occurrence of chronic ailments such as diabetes. Treatment for neurotrophic keratitis contributes to ocular well-being through enhanced corneal sensation, accelerated healing, infection deterrence, and pain reduction. Illustratively, data from August 2023, released by the World Health Organization (WHO), a Switzerland-based United Nations agency, revealed that approximately 2.2 billion people worldwide suffer from near or distance vision impairment. Of these, 1 billion cases could have been prevented or remain untreated. Furthermore, refractive errors and cataracts continue to be the primary global contributors to vision loss, yet only 36% of those with refractive-error-related distance impairment and a mere 17% of individuals with cataract-related impairment have accessed suitable medical attention. Consequently, the increasing occurrence of eye diseases is a significant impetus behind the expansion of the neurotrophic keratitis treatment market.
How Are Different Segments Classified In The Neurotrophic Keratitis Treatment Market Segment Analysis?
The neurotrophic keratitis treatment market covered in this report is segmented –
1) By Treatment: Topical Antibiotics, Recombinant Human Nerve Growth Factor (rhNGF), Amniotic Membrane Transplantation, Keratoplasty, Other Treatments
2) By Route Of Administration: Oral, Topical, Other Routes Of Administrations
3) By Application: Stage I, Stage II, Stage III
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Topical Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics
2) By Recombinant Human Nerve Growth Factor (rhNGF): Cenegermin Ophthalmic Solution
3) By Amniotic Membrane Transplantation: Cryopreserved Amniotic Membrane, Dehydrated Amniotic Membrane
4) By Keratoplasty: Penetrating Keratoplasty, Lamellar Keratoplasty
5) By Other Treatments: Tarsorrhaphy, Therapeutic Contact Lenses
What Emerging Trends Are Seen In The Neurotrophic Keratitis Treatment Market?
Major companies in the neurotrophic keratitis market are focusing on developing advanced gene-therapy solutions, such as redosable eye-drop therapies, to enhance corneal healing, maintain sustained nerve growth factor (NGF) expression, and reduce the patient treatment burden. Redosable eye-drop gene therapy describes a therapeutic method that delivers genes encoding NGF directly to the cornea, allowing for prolonged NGF production and supporting nerve regeneration over time. For instance, in July 2025, Krystal Biotech, a US-based biotechnology company, announced that the first patient was dosed in its Phase 1/2 EMERALD 1 study, a randomized, double-masked, placebo-controlled trial involving up to 27 adults with stage 2 or 3 neurotrophic keratitis. Designed for administration twice weekly for eight weeks, KB801 aims to safely promote corneal healing while significantly reducing the treatment burden compared to existing six-times-a-day recombinant NGF eye drops.
Who Are The Companies Driving Activity In The Neurotrophic Keratitis Treatment Market?
Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Johnson & Johnson, Allergan Inc, Alcon Inc, Bausch Health Companies Inc, Bausch & Lomb Inc, CooperVision Inc, Santen Pharmaceutical Co Ltd, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc, Laboratoires Thea SAS, ReGenTree LLC, Contacare Ophthalmic Private Limited, Neuroptika Inc, Surgitech Innovation Private Limited, Aerie Pharmaceuticals Inc, RegeneRx Biopharmaceuticals Inc, Noveome Biotherapeutics Inc, Oyster Point Pharma, Claris Biotherapeutics, Recordati Rare Diseases, Mitotech SA, Kala Pharmaceuticals, Oxurion NV
Get The Full Neurotrophic Keratitis Treatment Market Report:
Which Geographic Region Dominates The Neurotrophic Keratitis Treatment Market?
North America was the largest region in the neurotrophic keratitis treatment market in 2025. The regions covered in the neurotrophic keratitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Neurotrophic Keratitis Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Neurotrophic Keratitis Treatment Market 2026, By The Business Research Company
Neuroscience Market Report 2026
https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report
Neuroprosthetics Market Report
https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report
Neuromodulation Market Report
https://www.thebusinessresearchcompany.com/report/neuromodulation-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model